Company intelligence / Profile preview

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

Shanghai, Shanghai, Chinawigenbio.com ↗

Ownership: Private
Employees: ~80
Development stage: Other

Overview

The company has 6 products in Phase I clinical trials and 3 more in IND-enabling studies. Their lead candidate WJB001 has reached Phase 1/2 for advanced malignant solid neoplasms.

Therapeutic areas: OncologyImmunologyMetabolic Disorders
Modalities: Small molecule drugsChemical drugs
Industry: Biotech

Drug pipeline

12 assets

WJB001

11 more assets in the full pipeline.

Partnerships

Junshi Biosciences

Beyond the preview

Go deeper on Wigen Biomedicine Technology (Shanghai) Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wigen Biomedicine Technology (Shanghai) Co., Ltd..